Document is current
Any future updates will be listed below
-
Authors
Toprover, Michael
Shah, Binita
Oh, Cheongeun
Igel, Talia F.
Romero, Aaron Garza
Pike, Virginia C.
Curovic, Fatmira
Bang, Daisy
Lazaro, Deana
Krasnokutsky, Svetlana
Katz, Stuart D.
Pillinger, Michael H. http://orcid.org/0000-0003-3168-1542
-
Funding
Funding for this research was provided by:
New York State Department of Health (Empire Clinical Research Investigator Program)
Rheumatology Research Foundation (Investigator Award)
NYU Clinnical and Translational Science Institute (Pilot Project Award)
National Center for Advancing Translational Sciences (1UL1TR001445, 1UL1TR001445, 1UL1TR001445)
Biomedical Laboratory Research and Development, VA Office of Research and Development (1K2CS001074)
National Heart, Lung, and Blood Institute (R01HL146206)
- License Information
-
More Information
Article History
Received: 2 April 2020
Accepted: 2 July 2020
First Online: 11 July 2020
Ethics approval and consent to participate
: This study was approved by the Institutional Review Boards of NYU Langone Medical Center, Bellevue Hospital, and the New York Harbor Health Care System of the Department of Veterans Affairs. All subjects provided signed consent for participation.
: Not applicable.
: The authors declare that they have no direct competing interests relating to this study. For the purposes of full transparency, they offer the following disclosures. MT: nothing to disclose. BS: Philips Volcano Advisory Board; Radux Medical Advisory Board; Terumo Medical Consultant. CO. nothing to disclose. TFI: nothing to disclose. AGR: nothing to disclose. VCP: nothing to disclose. FC: nothing to disclose. DB: nothing to disclose. DL: nothing to disclose. SK: Investigator-initiated grant from Hikma Pharmaceuticals. SDK: nothing to disclose. MHP: Consultancies for Horizon Pharma, and Sobi, and investigator-initiated grants from Horizon Pharma and Hikma Pharmaceuticals.
